Adial Pharmaceuticals regains Nasdaq compliance, plans Phase 3 clinical trial for AUD treatment.

Adial Pharmaceuticals has regained compliance with Nasdaq's listing requirement, having maintained a minimum bid price of $1.00 per share for 10 consecutive business days. The company has now resolved its Nasdaq compliance issue and is advancing its AD04 treatment for addiction and related disorders. AD04 has shown promising results in reducing heavy drinking and has the potential to treat other addictive disorders. Adial is planning a new Phase 3 clinical trial program and is engaged in strategic partnering discussions to support further development and commercialization.